Freeze Now to Live Again Later? Tomorrow Bio Raises €5M and Eyes U.S. Breakthrough
Cryonics — a concept long caught between science and mythology — is finally stepping out of the realm of sci-fi and into the frontier of European high-tech innovation. What was once a fantastical trope — freezing the body to revive it in the future — is now a tangible technological ambition.
Berlin-based startup Tomorrow Bio, known as Europe’s first medically licensed cryonics center, has just raised €5 million and announced plans to enter the U.S. market. But behind the business lies a bold ideology: what its founders call a “revolution in long-term medical preservation.” Rather than curing, they propose preserving — waiting until science can catch up with disease.
The investors — including the Swiss foundation Clima Now and a German deeptech syndicate — believe cryonics is evolving from a fringe futurist fantasy into a field of real-world solutions. Tomorrow Bio has already cryopreserved dozens of bodies, including Austria’s first legal patient. The procedure starts immediately after legal death, and the team’s mission is to protect the brain with minimal cellular damage — ideally, until it can one day be rebooted.
Skeptics see this as a costly illusion. But with rapid advances in neurotechnology, nanomedicine, and tissue regeneration, their arguments are wearing thin. A world where death is not the end, but a pause — still feels unsettling. Yet it may be in labs like this that the era of a second life quietly begins.
Now Tomorrow Bio is growing its team, building mobile emergency cryoprotection capsules, and preparing for its first U.S. center. For the investors, this is about more than technology — it’s about reshaping our future, where time is no longer a sentence, but a variable.
